Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

CRINETICS PHARMACEUTICALS IN (CRNX)

236 + Investors. Track Smart Money conviction in CRNX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -5
Streak
1Q ▼
Buyers last Q
60%

Smart Money Signals — CRNX

Based on 238 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their CRNX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🏔️

At the ownership peak (98% of max)

98% of all-time peak
238 hedge funds hold CRNX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +8% more funds vs a year ago

fund count last 6Q
+17 new funds entered over the past year (+8% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟢

More buyers than sellers — 60% buying

163 buying108 selling
Last quarter: 163 funds were net buyers (44 opened a brand new position + 119 added to an existing one). Only 108 were sellers (59 trimmed + 49 sold completely). A clear majority buying is a strong confirmation signal.
⚠️

Fewer new buyers each quarter (-9 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 35 → 41 → 53 → 44. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

48% of holders stayed for 2+ years

■ 48% conviction (2yr+) ■ 24% medium ■ 28% new
115 out of 238 hedge funds have held CRNX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares +8%, value -18%

Value
-18%
Shares
+7%
Last quarter: funds added +8% more shares while total portfolio value only changed -18%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
📈

Growing discovery — still being found

38 → 35 → 41 → 53 → 44 new funds/Q
New funds entering each quarter: 35 → 41 → 53 → 44. A growing number of institutions are discovering CRNX each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Deep conviction — 51% of holders stayed 2+ years

■ 51% veterans ■ 17% 1-2yr ■ 32% new
Of 244 current holders: 124 (51%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
🏆

Elite ownership — 41% AUM from top-100 funds

41% from top-100 AUM funds
50 of 238 holders are among the 100 largest funds by AUM, controlling 41% of total institutional value in CRNX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.8
out of 10
Low Exit Risk
Exit risk score 3.8/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CRNX

In 2026 Q1, 163 hedge funds were net buyers of CRNX (44 opened a new position, 119 added to an existing one), while 108 reduced or exited (59 trimmed, 49 sold completely) — a 60% buyer ratio, indicating clear institutional accumulation. 41% of total institutional value in CRNX is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: -5 funds (more exits than new entries). Total institutional holders: 238.

Hedge Fund Ownership: CRNX

How many hedge funds hold CRNX — quarterly history vs. share price
Quarterly hedge fund ownership of CRNX vs. share price

Market Analysis: CRNX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CRNX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy CRINETICS PHARMACEUTICALS IN (CRNX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CRNX has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 71d ago
CRNX
-0.9%
XLV
+4.1%

CRNX outperformed XLV by -5.0% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 26d ago
CRNX
-9.4%
XLV
+5.2%

Since the filing became public, CRNX outperformed XLV by -14.6% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

23 top-rated funds 4 high-conviction
Consensus
6.0
/ 10
breadth
×
Elite
2.9
/ 10
conviction
Hedge Fund Positioning: CRNX
236 + Investors

Track Smart Money conviction in CRNX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 236 243 -2.88%
13F Shares 122M 113M 7.83%
Total Value $4.08B $5.00B -18.35%
New Positions 43 53 -10
Increased Positions 117 93 +24
Closed Positions 50 32 +18
Reduced Positions 57 78 -21
Total Calls 4 5 -20.0%
Total Puts 3 6 -50.0%
PUT/CALL Ratio 0.75 1.2 Neutral

Statistics: CRNX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

236 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CRNX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 institutional holders of CRNX — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 EcoR1 Capital, LLC 6.61% 4,288,120 $155.7M
2 Novo Holdings A/S 4.56% 1,550,000 $56.3M
3 First Light Asset Management, LLC 3.55% 1,089,670 $39.6M
4 GordonMD Global Investments LP 3.21% 126,985 $4.6M
5 Bellevue Group AG 2.84% 3,280,000 $119.1M
6 Semanteon Capital Management, LP 2.71% 5,562 $202K
7 ADAR1 Capital Management, LLC 2.44% 1,139,331 $41.4M
8 Prosight Management, LP 2.08% 350,000 $12.7M
9 Siren, L.L.C. 1.92% 1,903,636 $69.1M
10 FARALLON CAPITAL MANAGEMENT LLC 1.73% 8,338,098 $302.8M
11 DRIEHAUS CAPITAL MANAGEMENT LLC 1.71% 6,395,922 $232.3M
12 Foresite Capital Management VI LLC 1.67% 212,010 $7.7M
13 Sio Capital Management, LLC 1.30% 249,887 $9.1M
14 MOODY ALDRICH PARTNERS LLC 1.20% 183,438 $6.7M
15 SUVRETTA CAPITAL MANAGEMENT, LLC 0.97% 1,043,879 $37.9M
16 SECTOR GAMMA AS 0.81% 94,195 $3.4M
17 ORBIMED ADVISORS LLC 0.72% 999,000 $36.3M
18 RTW INVESTMENTS, LP 0.52% 1,451,326 $52.7M
19 Checkpoint Capital L.P. 0.52% 40,230 $1.5M
20 GW&K Investment Management, LLC 0.52% 1,618,686 $59K
21 BAKER BROS. ADVISORS LP 0.49% 2,351,465 $85.4M
22 Cormorant Asset Management, LP 0.46% 250,000 $9.1M
23 AWM Investment Company, Inc. 0.40% 100,000 $3.6M
24 RICE HALL JAMES & ASSOCIATES, LLC 0.40% 195,701 $7.1M
25 BRAUN STACEY ASSOCIATES INC 0.39% 324,808 $11.8M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — CRINETICS PHARMACEUTICALS IN (CRNX)

What does the Smart Money Trend signal show for CRNX?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their CRNX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for CRNX?

More buyers than sellers — 60% buying: Last quarter: 163 funds were net buyers (44 opened a brand new position + 119 added to an existing one). Only 108 were sellers (59 trimmed + 49 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for CRNX holders?

Elite ownership — 41% AUM from top-100 funds: 50 of 238 holders are among the 100 largest funds by AUM, controlling 41% of total institutional value in CRNX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held CRNX?

48% of holders stayed for 2+ years: 115 out of 238 hedge funds have held CRNX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy CRINETICS PHARMACEUTICALS IN (CRNX) following the 2026 Q1 hedge fund 13F filings?

As of today, CRNX has moved -9.4% since the 2026 Q1 13F filing date (May 15, 2026), compared to +5.2% for the XLV sector ETF — an outperformance of -14.6%. Since the quarter end (March 31, 2026), CRNX has gained -0.9% vs +4.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →